Superworth

CorMedix profit margin CRMD

Gross, operating and net profit as a share of revenue over the last twelve months, from 2025.

Net margin, 12 months
40.5%
Operating margin, 12 months
47.0%
Net margin on a year earlier
−1.6 pts
Peer median
11.2%

Over the twelve months to Jun 30, 2026, CorMedix kept 40.5% of its revenue as net profit, with an operating margin of 47.0% and a gross margin of 82.8%.

The median for 10 large drugmakers of a similar size is 11.2%.

Profit margin over time

GrossOperatingNet

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearNet marginOperating marginGross margin
FY202552.3%48.2%88.5%
FY2024n/an/an/a
FY2023n/an/an/a
FY2022n/an/a94.3%
FY2021n/an/a22.0%
FY2020n/an/a14.4%
FY2019n/an/a−31.8%
FY2018n/an/an/a
FY2017n/an/an/a
FY2016n/an/a−63.6%
FY2015n/an/an/a
FY2014n/an/an/a
FY2013n/an/an/a
FY2012n/an/an/a
FY2011n/an/an/a

Quarter by quarter

QuarterEndedNet margin, 12 monthsChange on a yearOperating margin
Q2 FY2640.5%−1.6 pts47.0%
Q1 FY2645.2%+24.4 pts48.4%
Q4 FY2552.3%n/a48.2%
Q3 FY2575.8%n/a48.5%
Q2 FY2542.1%n/a40.6%
Q1 FY2520.8%n/a17.5%
Q4 FY24n/an/an/a
Q3 FY24n/an/an/a
Q2 FY24n/an/an/a
Q1 FY24n/an/an/a
Q4 FY23n/an/an/a
Q3 FY23n/an/an/a

Against its peers

Companies in Drug Manufacturers - General nearest CorMedix's size, closest first, today.

CompanyProfit margin
CRMDCorMedix40.5%
ZVRAZevra Therapeutics42.8%
IRWDIronwood Pharmaceuticals33.4%
PBYIPuma Biotechnology11.6%
COLLCollegium Pharmaceutical5.9%
ARVNArvinas2.9%
ABUSArbutus Biopharma84.2%
AMPHAmphastar Pharmaceuticals10.8%
OMEROmerosn/m
PCRXPacira BioSciences2.0%
ANABAnaptysbion/m
Peer median11.2%

Where CorMedix ranks

What the profit margin tells you

Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).

Compare within an industry. 10% is superb for a retailer and poor for a software company.

More on CorMedix

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.